Cholangiocarcinoma (Bile Duct Cancer) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Cholangiocarcinoma (CCA) comprises a diverse range of bile duct neoplasms, ranking as the second most prevalent hepatic cancer after hepatocellular carcinoma. It is classified into intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA), with the latter encompassing perihilar cholangiocarcinoma (pCCA or Klatskin tumor) and distal cholangiocarcinoma (dCCA). Symptoms of cholangiocarcinoma encompass jaundice, dark urine, clay-colored stools, abdominal pain, fever, pruritus, nausea, vomiting, and unintended weight loss. Risk factors for this condition include: 1. Primary sclerosing cholangitis 2. Chronic ulcerative colitis 3. Bile duct cysts 4. Infection with the Chinese liver fluke parasite Staging of cholangiocarcinoma utilizes the TNM system, evaluating tumor size (T), involvement of lymph nodes (N), and presence of ...